Sign up Australia
Proactive Investors - Run By Investors For Investors

BioTech Capital signs strategic agreement with Swedish medtech player

The company has won the rights to distribute two dental products.
A dentist working on a patient
BioTech’s shares were last trading 11% higher intra-day

BioTech Capital Limited’s (ASX:BTC) wholly owned subsidiary BioImpact has extended its exclusive license and supply agreement with RLS Global AB to include two additional products.

BioTech is in the business of providing development capital and management expertise to high-growth Australian biotech, medtech and pharmaceutical companies.

RLS Global is a Swedish medtech company that develops and sells biochemical products and methods for the treatment of some of the world’s most common diseases.

BioImpact has won the rights to distribute RLS Global’s two dental products Perisolv and Carisolv within Australia, New Zealand and select countries across the Asia Pacific region.

Perisolv is a patented and biochemically active gel that optimises the dental professional’s treatment of advanced gum disorders like periodontitis, mucositis and peri-implantitis.

The gel when applied directly exerts a bacteriostatic effect and aids in dissolving degenerated tissue, making the debridement easier for both dental professionals and patients.

Carisolv is a patented gel that assists in the removal and treatment of dental caries. It is a minimally invasive treatment that gives better bonding strength to the filling.

Perisolv and Carisolv are classified as medical devices to be made available in Australia this financial year post inclusion in the Australian Register of Therapeutic Goods.

BioTech’s shares were last trading 11% higher intra-day, at $0.20.

View full BTC profile View Profile

Biotech Capital Ltd Timeline

February 13 2017
August 07 2014

Related Articles

Internet TV specialsit Falcon Media House transformed and ready to start generating revenues
August 26 2017
It has gone from a cash shell to fully fledged online TV company plugged into a massive market in a year and half
cannabis plant
February 02 2018
Today, the group closed the US$18mln acquisition of Citiva Medical and Citiva USA

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use